These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31645353)

  • 41. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
    Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
    Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients.
    Girinsky T; Aupérin A; Ribrag V; Elleuch M; Fermé C; Bonniaud G; Ruelle C; Alberini JL; Celebic A; Edeline V
    Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1047-1052. PubMed ID: 25035208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pulmonary lymphocyte-rich classical Hodgkin lymphoma with early response to ABVD therapy.
    Honda A; Nakamura F; Nannya Y; Shintani Y; Fukayama M; Ichikawa M; Kurokawa M
    Ann Hematol; 2014 Jun; 93(6):1073-4. PubMed ID: 24173088
    [No Abstract]   [Full Text] [Related]  

  • 44. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
    Vijenthira A; Chan K; Cheung MC; Prica A
    Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic Value of 2-[(18)F] Fluoro-2-deoxy-D-glucose Positron Emission Tomography-Computed Tomography Scan Carried out During and After Radiation Therapy for Head and Neck Cancer Using Visual Therapy Response Interpretation Criteria.
    Min M; Lin P; Lee M; Ho Shon I; Lin M; Forstner D; Tieu MT; Chicco A; Bray V; Fowler A
    Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):393-401. PubMed ID: 26782837
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
    Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy.
    Hoppe BS; McCarten KM; Pei Q; Kessel S; Alazraki A; Mhlanga JC; Lai HA; Eutsler E; Hodgson DC; Roberts KB; Charpentier AM; Keller FG; Voss SD; Wu Y; Cho SY; Kelly KM; Castellino SM
    Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1025-1030. PubMed ID: 36868525
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
    Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
    Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.
    Raemaekers JM; André MP; Federico M; Girinsky T; Oumedaly R; Brusamolino E; Brice P; Fermé C; van der Maazen R; Gotti M; Bouabdallah R; Sebban CJ; Lievens Y; Re A; Stamatoullas A; Morschhauser F; Lugtenburg PJ; Abruzzese E; Olivier P; Casasnovas RO; van Imhoff G; Raveloarivahy T; Bellei M; van der Borght T; Bardet S; Versari A; Hutchings M; Meignan M; Fortpied C
    J Clin Oncol; 2014 Apr; 32(12):1188-94. PubMed ID: 24637998
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose/positron-emission tomography in advanced Hodgkin lymphoma.
    Biggi A; Bergesio F; Chauvie S; Bianchi A; Menga M; Fallanca F; Hutchings M; Gregianin M; Meignan M; Gallamini A
    Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):410-415. PubMed ID: 28750493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma: response to Adams and Kwee.
    Milgrom SA; Pinnix CC; Gunther JR; Fanale M; Dabaja BS
    Br J Haematol; 2019 Jan; 184(2):292-293. PubMed ID: 29265334
    [No Abstract]   [Full Text] [Related]  

  • 54. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
    Ogura M; Itoh K; Ishizawa K; Kobayashi Y; Tobinai K; Kinoshita T; Hirano M; Ueda R; Shibata T; Nakamura S; Tsukasaki K; Hotta T; Shimoyama M; Morishima Y;
    Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma.
    Adams HJA; Kwee TC
    Br J Haematol; 2019 Jan; 184(2):290-292. PubMed ID: 29265351
    [No Abstract]   [Full Text] [Related]  

  • 56. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
    Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
    Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Can We Predict Bleomycin Toxicity with PET-CT?
    Beyhan Sagmen S; Comert S; Turan Erkek E; Küçüköz Uzun A; Doğan C; Yılmaz G; Kıral N; Fidan A; Yılmaz Haksal Ç; Torun Parmaksız E
    Acta Haematol; 2019; 142(3):171-175. PubMed ID: 31454795
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma.
    Reid JH; Marini BL; Nachar VR; Brown AM; Devata S; Perissinotti AJ
    Crit Rev Oncol Hematol; 2020 Apr; 148():102897. PubMed ID: 32109715
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ABVD Without Radiation for Newly Diagnosed Pediatric and Young Adult Patients With Hodgkin Lymphoma: A Single Center Retrospective Analysis of 28 Consecutive Patients.
    Stieglitz E; Dinh T; Phelps AS; Pampaloni MH; Olshen AB; Robbins E
    J Pediatr Hematol Oncol; 2018 May; 40(4):290-294. PubMed ID: 29432308
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Limited-stage Hodgkin lymphoma: optimal chemotherapy and the role of radiotherapy.
    Bartlett NL
    Am Soc Clin Oncol Educ Book; 2013; ():374-80. PubMed ID: 23714551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.